EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network

Sebastian Yu, An-Ping Huo, Yu-Hsun Wang, James Cheng-Chung Wei

BioDrugs · 2025

DOI: 10.1007/s40259-025-00705-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BioDrugs, 2025. Verfasst von Sebastian Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Interleukin-23, Psoriasis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burden. Biologic therapies targeting the interleukin (IL)-23/IL-17 axis have been widely used for PsO, but their comparative effectiveness in preventing PsA remains unclear. OBJECTIVE: The study objective was to compare the occurrence of developing incidental PsA among PsO patients treated with interleukin-23 inhibitors (IL23is) or interleukin-17 inhibitors (IL17is). METHODS: A retrospective cohort study was conducted using real-world data from the TriNetX US Collaborative Network, including 53 healthcare organizations. Adult PsO patients treated with IL23is or IL17is between January 2019 and June 2022 were identified. Cox regression analysis was used to assess the risk of PsA incidence, with hazard ratios (HRs) and 95% confidence intervals (CIs) reported. Subgroup analyses were performed based on age, sex, and ethnicity. Sensitivity analyses included comparisons with tumor necrosis factor (TNF) inhibitors (TNFis) to ensure robustness. RESULTS: A total of 4,580 PsO patients were included in the study, with 2,273 receiving IL23is and 2,307 receiving IL17is. Treatment with IL23is was associated with a significantly lower incidence of PsA compared to IL17is (HR = 0.60, 95% CI 0.44-0.82, P = 0.001). This reduction in risk was particularly notable in the 41- to 65-year age group (HR = 0.42, 95% CI 0.27-0.64, P < 0.001) and among females (HR = 0.57, 95% CI 0.38-0.86, P = 0.007). Subgroup analyses based on ethnicity revealed varying outcomes, with White patients showing a significant risk reduction (HR = 0.55, 95% CI 0.38-0.79, P = 0.001) but no significant risk reduction was observed in Black or African American patients (HR = 1.37, 95% CI 0.37-5.13, P = 0.637). Sensitivity analyses comparing IL23is and TNFis confirmed the robustness of the findings. CONCLUSION: IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups. These findings suggest that IL23is may be more suitable for PsO patients at high risk of PsA and could inform potential updates to treatment guidelines. Further research should focus on refining therapeutic strategies by incorporating patient-specific factors such as comorbidities, ethnicity, and genetic predispositions, which could optimize biologic selection and enhance PsA prevention efforts in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticInterleukin-17Interleukin-23PsoriasisHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedIncidenceTumor Necrosis Factor InhibitorsUnited States

Substanzen

Interleukin-17Interleukin-23Tumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Dermatology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan.
  • Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • Master of Public Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Allergy, Immunology and Rheumatology, South District, Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd, Taichung City, 40201, Taiwan.

Förderung

  • National Science and Technology Council

Zitieren

APA

Yu, S., Huo, A. P., Wang, Y. H., & Wei, J. C. (2025). Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network. BioDrugs. https://doi.org/10.1007/s40259-025-00705-5

Vancouver

Yu S, Huo AP, Wang YH, Wei JC. Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network. BioDrugs. 2025. doi:10.1007/s40259-025-00705-5

BibTeX
@article{Yu2025,
  author = {Yu, Sebastian and Huo, An-Ping and Wang, Yu-Hsun and Wei, James Cheng-Chung},
  title = {Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network},
  journal = {BioDrugs},
  year = {2025},
  doi = {10.1007/s40259-025-00705-5}
}
Kostenlos starten →